Hepatitis C in Argentina: epidemiology and treatment

Código QR

Hepatitis C in Argentina: epidemiology and treatment

Luis Alejandro Gaite, Sebastián Marciano, Omar Andrés Galdame, Adrián Carlos GadanoHepatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, and liver cancer in Argentina, w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gaite LA, Marciano S, Galdame OA, Gadano AC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/625cdf132bc54934940b49a496d92edf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Epidemiology and treatment of autoimmune hepatitis
por: Francque S, et al.
Publicado: (2012)

Interferon-free combination therapies for the treatment of hepatitis C: current insights
por: Holmes JA, et al.
Publicado: (2015)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
por: Degasperi E, et al.
Publicado: (2014)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia MD, et al.
Publicado: (2011)

Ending hepatitis C in the United States: the role of screening
por: Coffin PO, et al.
Publicado: (2014)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish FA, et al.
Publicado: (2013)

Novel drugs in the management of difficult-to-treat hepatitis C genotypes
por: Cartwright EJ, et al.
Publicado: (2013)

Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
por: Gomaa A, et al.
Publicado: (2017)

Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program
por: Cervio G, et al.
Publicado: (2011)

New-onset ascites as a manifestation of virologic relapse in patients with hepatitis C cirrhosis
por: Chua DL, et al.
Publicado: (2014)

Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus
por: Bruno S, et al.
Publicado: (2011)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal SM
Publicado: (2014)

Selected biochemical and hematological abnormalities in Nigerians with human immunodeficiency virus and hepatitis C virus coinfection
por: Nwokediuko SC, et al.
Publicado: (2011)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

Epidemiology of drug-induced liver injury
por: LI Xiaoyun
Publicado: (2021)

Association of cytokine gene polymorphisms with hepatitis C virus infection in a population from Rio de Janeiro, Brazil
por: Fabrício-Silva GM, et al.
Publicado: (2015)

Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina
por: Espul C, et al.
Publicado: (2012)

Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans
por: Neil Heraghty, et al.
Publicado: (2021)

Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study
por: Kawanaka M, et al.
Publicado: (2013)

Reply to: “Hepatic bile acid transport increases in the postprandial state: A functional 11C-CSar PET/CT study in healthy humans”
por: Nikolaj W. Ørntoft, et al.
Publicado: (2021)

Transmission, diagnosis, and management of hepatitis E: an update
por: Mirazo S, et al.
Publicado: (2014)

Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
por: Dhanasekaran R, et al.
Publicado: (2012)

Update on entecavir in the management of severe forms of Hepatitis B
por: Sacco R
Publicado: (2012)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
por: Ismail MH, et al.
Publicado: (2011)

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
por: Roggeri DP, et al.
Publicado: (2015)

A high prevalence of extreme hyperferritinemia in acute hepatitis patients
por: Kazuhiro Kotoh, et al.
Publicado: (2009)

Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
por: JIANG Jun
Publicado: (2021)

Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients
por: Bertr, et al.
Publicado: (2015)

Risk Prediction of Nosocomial and Posthospital Discharge Infections in Alcohol‐Associated Hepatitis
por: Daniel D. Penrice, et al.
Publicado: (2021)

A case of hepatic portal venous gas due to viral gastroenteritis
por: Mirmanesh M, et al.
Publicado: (2013)

Clinical features and prognosis of primary myelofibrosis with hepatic vascular disease and/or portal hypertension
por: WANG Jing
Publicado: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
por: JIANG Yingying
Publicado: (2021)

Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
por: Lau T, et al.
Publicado: (2013)

Association between hepatic fat and subclinical vascular disease burden in the general population
por: Susanne Rospleszcz, et al.
Publicado: (2021)

Establishment and evaluation of a nomogram for predicting post-hepatectomy complications in two types of hepatic echinococcosis
por: GUO Bing
Publicado: (2021)

How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
por: DING Yang
Publicado: (2021)

Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics
por: Magda Shaheen, et al.
Publicado: (2021)

Serum anti-modified citrullinated vimentin antibody concentration is associated with liver fibrosis in patients with chronic hepatitis
por: Suad Abdeen, et al.
Publicado: (2011)

Patients with chronic hepatitis B virus infection in the indeterminate phase may benefit from antiviral therapy
por: XU Jinghang
Publicado: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy
por: WANG Jingyue
Publicado: (2021)